ABSTRACT
In a context where the availability of information represents the opportunity for companies to gain a competitive advantage in the market through the use of sophisticated AI algorithms, data quality assumes a strategic role. With this paper we want to show that the adoption of an international quality measurement standard such as the one present in the SQuaRE series can on the one hand improve the ethical aspect of machine learning algorithms and on the other hand meet the requirements imposed by the European Community regarding the protection of personal data of citizens in Member States (GDPR). Indeed, although the attention to the protection of personal data is mainly directed towards the aspects of security and confidentiality, in a holistic view we should also evaluate the risks arising from the absence of quality in the data. In this context, we consider consistent and of reference for the international community the choice of the Italian legislator made for the Public Administrations. Since 2013 the Agency for Digital Italy (AgID) has suggested the adoption of ISO/IEC 25012 for public administrations in charge of managing databases of national interest. In the article, we propose a methodological approach that ensures the governance of data quality and some open questions regarding the homogeneity of the selected measures. © 2021 for this paper by its authors
ABSTRACT
Individuals with malignancies and COVID-19 have a lower survival compared with the general population. However, the information about the impact of COVID-19 on the whole hematological population is scarce. We aimed to describe the 30th day overall survival (OS) after COVID-19 infection in patients with a hematological disease in Argentina. A completely anonymous survey from the Argentine Society of Hematology was delivered to all the hematologists in Argentina;it started in April 2020. A cut-off to analyze the data was performed in December 2020 and, finally, 419 patients were reported and suitable for the analysis (average age: 58 years, 90% with malignant diseases). After the COVID-19 diagnosis, the 30-day OS for the whole population was 80.2%. From the entire group (419), 101 (24.1%) individuals required intensive care unit admission, where the 30-day OS was 46.6%. Among allogeneic stem cell transplant recipients, the 30-day OS was 70.3%. Factors associated with a low OS were two or more comorbidities, an active hematological disease and history of chemotherapy. In individuals with the three factors, the 30-day OS was 49.6% while the 30-day OS in those without those factors was 100%. Patients with hematological diseases have a higher mortality than the general population. This group represents a challenge and requires careful decision-making of the treatment in order not to compromise the chances of cure.